Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population

References

• Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002; 12: 703–711
   PubMedGoogle Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology 1994a; 46: 594–598
   PubMed Web of Science ®Google Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry 1994b; 269: 15419–15422
   PubMed Web of Science ®Google Scholar
• Ferguson RJ, de Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, et al. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. Journal of Pharmacology and Experimental Therapeutics 1998; 284: 356–361
   PubMed Web of Science ®Google Scholar
• Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, Azuma J. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6 * 10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Archives of Biochemistry and Biophysics 2000; 380: 303–308
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, et al. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metabolism and Pharmacokinetics 2005; 20: 300–307
   PubMedGoogle Scholar
• Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Annals of Internal Medicine 1998; 129: 1027–1030
   PubMed Web of Science ®Google Scholar
• Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M, Kosuge K, Hanai H, Chiba K, et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clinical Pharmacology and Therapeutics 1999; 66: 265–274
   PubMed Web of Science ®Google Scholar
• Garcia-Barcelo M, Chow LY, Kum Chiu HF, Wing YK, Shing Lee DT, Lam KL, Waye MM. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: Detection of the rare allele CYP2C19*4. Clinical Chemistry 1999; 45: 2273–2274
   PubMed Web of Science ®Google Scholar
• Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology 2001; 52: 349–355
   PubMed Web of Science ®Google Scholar
• Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285–299
   PubMedGoogle Scholar
• Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743–1752
   PubMed Web of Science ®Google Scholar
• Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995; 28: 328–332
   PubMed Web of Science ®Google Scholar
• Hanioka N, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, Sawada J. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzyme. Drug Metabolism and Disposition 2002; 30: 391–396
   PubMed Web of Science ®Google Scholar
• Hichiya H, Takemi C, Tsuzuki D, Yamamoto S, Asaoka K, Suzuki S, Satoh T, Shinoda S, Kataoka H, Narimatsu S. Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver. Biochemical Pharmacology 2002; 64: 1101–1110
   PubMed Web of Science ®Google Scholar
• Ibeanu GC, Ghanayem BI, Linko P, Li L, Pederson LG, Goldstein JA. Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity. Journal of Biological Chemistry 1996; 271: 12496–12501
   PubMed Web of Science ®Google Scholar
• Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998a; 8: 129–135
   PubMedGoogle Scholar
• Ibeanu GC, Goldstein JA, Meyer UA, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. Journal of Pharmacology and Experimental Therapeutics 1998b; 286: 1490–1495
   PubMed Web of Science ®Google Scholar
• Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. Journal of Pharmacology and Experimental Therapeutics 1999; 290: 635–640
   PubMed Web of Science ®Google Scholar
• Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Molecular Pharmacology 1994; 46: 452–459
   PubMed Web of Science ®Google Scholar
• Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. European Journal of Clinical Pharmacology 1997; 5: 391–396
   Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Lewis DF. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002; 32: 305–323
   PubMedGoogle Scholar
• Lewis DF. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Archives of Biochemistry and Biophysics 2003; 409: 32–44
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Miners JO, Coulter S, Birkett DJ, Goldstein JA. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 2000; 10: 267–270
   PubMedGoogle Scholar
• Morita J, Kobayashi K, Wanibuchi A, Kimura M, Irie S, Ishizaki T, Chiba K. A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4′-hydroxylation. Drug Metabolism and Pharmacokinetics 2004; 19: 236–238
   PubMedGoogle Scholar
• Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
   PubMedGoogle Scholar
• Niwa T, Kageyama A, Kishimoto K, Yabusaki Y, Ishibashi F, Katagiri M. Amino acid residues affecting the activities of human cytochrome P450 2C9 and 2C19. Drug Metabolism and Disposition 2002; 30: 931–936
   PubMed Web of Science ®Google Scholar
• Oda A, Yamaotsu N, Hirono S. Studies of binding modes of (S)-mephenytoin to wild types and mutants of cytochrome P450 2C19 and 2C9 using homology modeling and computational docking. Pharmaceutical Research 2004; 21: 2270–2278
   PubMedGoogle Scholar
• Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry 1964; 239: 2370–2378
   PubMed Web of Science ®Google Scholar
• Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clinical Pharmacology and Therapeutics 1999; 66: 642–646
   PubMed Web of Science ®Google Scholar
• Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews 1997; 29: 413–580
   PubMed Web of Science ®Google Scholar
• Romanos MA, Scorer CA, Clare JJ. Foreign gene expression in yeast: A review. Yeast 1992; 8: 423–488
   PubMed Web of Science ®Google Scholar
• Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30: 3247–3255
   PubMed Web of Science ®Google Scholar
• Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. Crystal structure of human cytochrome P450 2D6. Journal of Biological Chemistry 2006; 281: 7614–7622
   PubMed Web of Science ®Google Scholar
• Sakaki T, Akiyoshi-Shibata M, Yabusaki Y, Ohkawa H. Organella-targeted expression of rat liver cytochrome P450c27 in yeast: genetically engineered alteration of mitochondrial P450 into a microsomal form creates a novel functional electron transport chain. Journal of Biological Chemistry 1992; 267: 16497–16502
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. Structure of human microsomal cytochrome P450 2C8: Evidence for a peripheral fatty acid binding site. Journal of Biological Chemistry 2004; 279: 9497–9503
   PubMed Web of Science ®Google Scholar
• Scott EE, White MA, He YA, Johnson EF, Stout CD, Halpert JR. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-Å resolution: Insight into the range of P450 conformations and the coordination of redox partner binding. Journal of Biological Chemistry 2004; 279: 27294–27301
   PubMed Web of Science ®Google Scholar
• Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology and Therapeutics 2006; 79: 103–113
   PubMed Web of Science ®Google Scholar
• Tsao CC, Wester MR, Ghanayem B, Coulter SJ, Chanas B, Johnson EF, Goldstein JA. Identification of human CYP2C19 residues that confer S-mephenytoin 4′-hydroxylation activity to CYP2C9. Biochemistry 2001; 20: 1937–1944
   Google Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proceedings of the National Academy of Sciences. USA 1979; 76: 4350–4354
   Google Scholar
• Wan J, Imaoka S, Chow T, Hiroi T, Yabusaki Y, Funae Y. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Archives of Biochemistry and Biophysics 1997; 348: 383–390
   PubMed Web of Science ®Google Scholar
• Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology 2000; 61: 174–183
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity. Molecular Cell 2000; 5: 121–131
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Ward A, Angove HC, Vinković DM, Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424: 464–468
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Vinković DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004; 305: 683–686
   PubMed Web of Science ®Google Scholar
• Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Journal of Pharmacology and Experimental Therapeutics 1997; 281: 604–609
   PubMed Web of Science ®Google Scholar